The chaperone activity of α-synuclein: Utilizing deletion mutants to map its interaction with target proteins

Proteins: Structure, Function and Bioinformatics

Volumn 80, Issue 5, 2012, Pages 1316-1325

  Rekas, Agata ^a   Ahn, Keun Jae ^b   Kim, Jongsun ^b   Carver, John A ^c  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^b Yonsei University   (South Korea)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Aggregation; Amyloid fibril; Binding site; Circular dichroism; Dynamic light scattering; Parkinson's disease; Thioflavin T

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; CHAPERONE; THIOFLAVINE;

AMINO TERMINAL SEQUENCE; ARTICLE; BETA SHEET; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; CORRELATION ANALYSIS; LIGHT SCATTERING; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN INTERACTION; TRANSMISSION ELECTRON MICROSCOPY;

ALPHA-SYNUCLEIN; AMYLOID; BINDING SITES; CIRCULAR DICHROISM; HUMANS; LIGHT; MOLECULAR CHAPERONES; PEPTIDE FRAGMENTS; PROTEIN INTERACTION MAPPING; RECOMBINANT PROTEINS; SCATTERING, RADIATION; SEQUENCE DELETION;

EID: 84862811649     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24028     Document Type: Article

References (36)

1. Goedert M, Spillantini MG, Davies SW. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol 1998; 8: 619-632.
2. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469-6473.
3. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT, Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996; 35: 13709-13715.
4. Kim J. Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil. Mol Cells 1997; 7: 78-83.
5. Dunker AK, Brown CJ, Lawson JD, Iakoucheva LM, Obradovic Z. Intrinsic disorder and protein function. Biochemistry 2002; 41: 6573-6582.
6. Kim TD, Paik SR, Yang CH, Kim J. Structural changes in alpha-synuclein affect its chaperone-like activity in vitro. Protein Sci 2000; 9: 2489-2496.
7. Souza JM, Giasson BI, Lee VM, Ischiropoulos H. Chaperone-like activity of synucleins. FEBS Lett 2000; 474: 116-119.
8. Rekas A, Adda CG, Aquilina JA, Barnham KJ, Sunde M, Galatis D, Williamson NA, Masters CL, Anders RF, Robinson CV, Cappai R, Carver JA. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. J Mol Biol 2004; 340: 1167-1183.
9. Rekas A, Jankova L, Thorn DC, Cappai R, Carver JA. Monitoring the prevention of amyloid fibril formation by alpha-crystallin. Temperature dependence and the nature of the aggregating species. FEBS J 2007; 274: 6290-6304.
10. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999; 19: 5782-5791.
11. Williams DM, Ecroyd H, Goodwin KL, Dai H, Fu H, Woodcock JM, Zhang L, Carver JA. NMR spectroscopy of 14-3-3zeta reveals a flexible C-terminal extension: differentiation of the chaperone and phosphoserine-binding activities of 14-3-3zeta. Biochem J 2011; 437: 493-503.
12. da Costa CA, Ancolio K, Checler F. Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J Biol Chem 2000; 275: 24065-24069.
13. Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 2000; 97: 279-284.
14. Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011; 477: 107-110.
15. Park SM, Jung HY, Chung KC, Rhim H, Park JH, Kim J. Stress-induced aggregation profiles of GST-alpha-synuclein fusion proteins: role of the C-terminal acidic tail of alpha-synuclein in protein thermosolubility and stability. Biochemistry 2002; 41: 4137-4146.
16. Park SM, Jung HY, Kim TD, Park JH, Yang CH, Kim J. Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone. J Biol Chem 2002; 277: 28512-28520.
17. Choi JY, Sung YM, Park HJ, Hur EH, Lee SJ, Hahn C, Min BR, Kim IK, Kang S, Rhim H. Rapid purification and analysis of alpha-synuclein proteins: C-terminal truncation promotes the conversion of alpha-synuclein into a protease-sensitive form in Escherichia coli. Biotechnol Appl Biochem 2002; 36: 33-40.
18. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 2005; 280: 22670-22678.
19. Horwitz J, Huang QL, Ding L, Bova MP. Lens alpha-crystallin: chaperone-like properties. Methods Enzymol 1998; 290: 365-383.
20. Dusa A, Kaylor J, Edridge S, Bodner N, Hong DP, Fink AL. Characterization of oligomers during alpha-synuclein aggregation using intrinsic tryptophan fluorescence. Biochemistry 2006; 45: 2752-2760.
21. Uversky VN, Lee HJ, Li J, Fink AL, Lee SJ. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem 2001; 276: 43495-43498.
22. Rekas A, Lo V, Gadd GE, Cappai R, Yun SI. PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein. Macromol Biosci 2009; 9: 230-238.
23. Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V. Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol 2002; 322: 383-393.
24. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 11282-11286.
25. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998; 4: 1318-1320.
26. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT, Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000; 97: 571-576.
27. Weinreb O, van Rijk AF, Dovrat A, Bloemendal H. In vitro filament-like formation upon interaction between lens alpha-crystallin and betaL-crystallin promoted by stress. Invest Ophthalmol Vis Sci 2000; 41: 3893-3897.
28. Kim TD, Paik SR, Yang CH. Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 2002; 41: 13782-13790.
29. Zhu M, Fink AL. Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem 2003; 278: 16873-16877.
30. Hudson SA, Ecroyd H, Kee TW, Carver JA. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J 2009; 276: 5960-5972.
31. Hoyer W, Cherny D, Subramaniam V, Jovin TM. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 2004; 43: 16233-16242.
32. Uversky VN, Fink AL. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta 2004; 1698: 131-153.
33. Stoppini M, Andreola A, Foresti G, Bellotti V. Neurodegenerative diseases caused by protein aggregation: a phenomenon at the borderline between molecular evolution and ageing. Pharmacol Res 2004; 50: 419-431.
34. Carver JA, Rekas A, Thorn DC, Wilson MR. Small heat-shock proteins and clusterin: intra- and extracellular molecular chaperones with a common mechanism of action and function? IUBMB Life 2003; 65: 661-668.
35. Meehan S, Berry Y, Luisi B, Dobson CM, Carver JA, MacPhee CE. Amyloid fibril formation by lens crystallin proteins and its implications for cataract formation. J Biol Chem 2004; 279: 3413-3419.
36. Meehan S, Knowles TP, Baldwin AJ, Smith JF, Squires AM, Clements P, Treweek TM, Ecroyd H, Tartaglia GG, Vendruscolo M, Macphee CE, Dobson CM, Carver JA. Characterisation of amyloid fibril formation by small heat-shock chaperone proteins human alphaA-, alphaB- and R120G alphaB-crystallins. J Mol Biol 2007; 372: 470-484.